CONMED (CNMD) vs Penumbra (PEN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Penumbra (PEN) has outperformed CONMED (CNMD) over the past year, gaining 22.2% versus a loss of 2.2%. Over five years, PEN leads with a +19.3% price change compared with -68.7% for CNMD. Penumbra is the larger company by market cap ($12.58 billion vs $1.33 billion), about 9.5 times the size.
On valuation, CONMED trades at a lower forward P/E (9.3x vs 52.1x for Penumbra). CONMED pays a dividend yielding 0.45%, while Penumbra does not currently pay one. Penumbra converts more of its revenue into profit, with a net margin of 12.7% versus 3.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CNMD | PEN |
|---|---|---|
| Share price | $44.42 | $319.40 |
| Market cap | $1.33B | $12.58B |
| 1-day change | -1.53% | +0.59% |
| YTD return | +9.41% | +2.73% |
| 1-year return | -2.18% | +22.19% |
| 5-year return | -68.72% | +19.29% |
| P/E ratio (TTM) | 24.01 | 78.48 |
| Forward P/E | 9.29 | 52.09 |
| EPS (TTM) | $1.85 | $4.07 |
| Dividend yield | 0.45% | 0.00% |
| Annual dividend | $0.20 | $0.00 |
| Revenue (latest FY) | $1.37B | $1.40B |
| Revenue growth (YoY) | +5.18% | +17.50% |
| Net income (latest FY) | $47.05M | $177.69M |
| Gross margin | 54.59% | 67.14% |
| Operating margin | 7.46% | 13.48% |
| Net margin | 3.42% | 12.66% |
| 52-week high | $53.66 | $362.41 |
| 52-week low | $31.44 | $221.26 |
| Distance from 52-week high | -17.22% | -11.87% |
| Analyst consensus | none | hold |
| Avg. price target upside | +2.43% | +13.21% |
| Average volume | 466.28K | 354.95K |
| Shares outstanding | 29.95M | 39.39M |
| Employees | 3,900 | 4,700 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Penumbra is about 9.5 times larger than CONMED by market value ($12.58B vs $1.33B).
- PEN has outperformed CNMD by 24.4 percentage points over the past year.
- Penumbra trades at a higher earnings multiple (78.5x vs 24.0x trailing P/E).
- Penumbra is more profitable, keeping 12.7 cents of every revenue dollar as net income versus 3.4 cents for CONMED.
- Penumbra grew revenue faster in its latest fiscal year (+17.50% vs +5.18%).
About CONMED
CNMD stock →CONMED Corporation, a medical technology company, develops, manufactures, and sells devices and equipment for surgical procedures. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as powered resection instruments, fluid management and visualization systems, and related single-use products that enable surgeons to perform minimally invasive sports medicine surgeries.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 3,900 employees
About Penumbra
PEN stock →Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.
Health Care · Medical/Dental Instruments · 4,700 employees
CNMD vs PEN FAQ
Which is bigger, CONMED or Penumbra?
Penumbra (PEN) is larger, with a market capitalization of $12.58B compared with $1.33B for CONMED (CNMD).
Which stock has performed better over the past year, CNMD or PEN?
PEN returned +22.19% over the past 12 months, compared with -2.18% for CNMD (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, CNMD or PEN?
CNMD has the lower trailing P/E at 24.0, versus 78.5 for PEN. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, CONMED or Penumbra?
CONMED pays a dividend yielding 0.45%, while Penumbra does not currently pay a regular dividend.
Are CONMED and Penumbra in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Electromedical & Electrotherapeutic Apparatus for CONMED and Medical/Dental Instruments for Penumbra.